Looking for the right type

GlobeImmune hopes genotyping will show where GI-5005 can improve HCV clearance

Although GlobeImmune Inc.'s GI-5005 Tarmogen immunotherapy failed a Phase IIb trial to treat chronic HCV infection, a new subgroup analysis based on IL-28B genotypes shows improvements in viral clearance were greatest in the genotypes associated with the poorest response to interferon-based treatment.

The company now plans to use IL-28B genotyping to stratify patients for a Phase III trial of GI-5005, and expects the process to become standard practice in HCV treatment and clinical development.

Tarmogens are whole, heat-killed, recombinant Saccharomyces cerevisiae that are genetically modified to express a disease-associated antigen to produce an

Read the full 910 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE